Twist Bioscience (NASDAQ:TWST) CFO Adam Laponis Sells 2,517 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 2,517 shares of Twist Bioscience stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $32.92, for a total transaction of $82,859.64. Following the completion of the sale, the chief financial officer owned 91,525 shares of the company’s stock, valued at $3,013,003. This represents a 2.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Adam Laponis also recently made the following trade(s):

• On Wednesday, October 8th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The shares were sold at an average price of $31.15, for a total transaction of $93,450.00.
• On Monday, October 6th, Adam Laponis sold 5,875 shares of Twist Bioscience stock. The shares were sold at an average price of $32.19, for a total transaction of $189,116.25.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $31.19 on Friday. The company has a fifty day moving average of $27.63 and a 200-day moving average of $32.66. The firm has a market capitalization of $1.88 billion, a P/E ratio of -21.51 and a beta of 2.38. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a twelve month low of $24.07 and a twelve month high of $55.33.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Barclays dropped their price objective on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, October 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Finally, Evercore ISI dropped their price objective on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after buying an additional 303 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after buying an additional 302 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Twist Bioscience in the 2nd quarter worth about $97,000. Bayforest Capital Ltd boosted its holdings in shares of Twist Bioscience by 49.3% in the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock worth $191,000 after buying an additional 1,604 shares during the last quarter. Finally, Pallas Capital Advisors LLC purchased a new position in shares of Twist Bioscience in the 1st quarter worth about $201,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.